🔗 Share this article

Given that the US continues making sweeping revisions to its immunization schedules, one figure has surfaced somewhat surprisingly: Høeg, a US-based physician and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccines throughout the global health crisis and has zeroed in on possible fatalities following Covid immunization in her short tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Schedule

Agency leaders planned to announce radical changes to the childhood vaccination calendar recently, bringing the US with the Danish vaccine program, according to reports – a major change that would place the US out of step with a large portion of the international standard with little proof for benefit. The announcement has been postponed until the new year.

Instead of Vinay Prasad, Høeg is listed to address the audience at the meeting. She was just designated acting director of the FDA’s CDER, the fifth individual to head the division this year.

A Shift at the Regulatory Body

The acting appointment could signify a tighter collaboration between the drug and vaccine centers as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing some childhood vaccine recommendations in the US so as to align more in line with the Danish model, a country with comprehensive healthcare and a population about the size of the state of Wisconsin.

To date comments, she has persisted in emphasizing on immunizations – usually the domain of Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Background

Dr. Høeg has no obvious background in pharmaceutical research, oversight or administrative roles, which has been customary for previous heads of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, stated Jonathan Howard. “She has not conducted a scientific study. She is not versed in running a sizeable institution. She lacks background in industry regulation.”

Former heads of the center would “grasp laws and regulations and the underlying principles of drug development”, commented a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that prior appointees who ran the center have had.”

The drug center has an immense workload at the FDA, she stated.

“Everybody just focuses on the new drug program, but the off-patent medication office authorizes a multitude of generic medications. There is also a biosimilars division, non-prescription drug unit and more, and each of these need to be managed,” Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial leadership component to the job, which oversees more than 5,000 employees. “It is a enormous leadership role, if you perform it correctly,” the former official added.

Response and Disputed Programs

Regarding concerns about Dr. Høeg's qualifications and whether this appointment indicates increased cooperation among FDA leaders on vaccines, a representative said that the “inquiries are based on inaccurate presumptions”.

“This background matches the responsibilities of her role,” the official said, noting the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the agency head's recently launched expedited review system, a disputed rapid drug-approval program that allegedly worried her predecessors. “By what process are these drugs being selected for this fast-track system? Who is making the choices?” Howard asked. “There’s a lot of confidentiality occurring at the FDA right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed oversight of most medications, with the exception of shots.”

Public Past Work on Immunizations

Regarding vaccines, Høeg has a clearer, if concerning, track record, some experts observe. She published a study using unconfirmed crowd-sourced reports to assess the frequency of heart inflammation following COVID-19 immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccines are riskier than they are.

Part of her “policy goals” for the current government included changing rules for recently developed shots and discontinuing “non-essential” immunizations, she stated post-election on a online show. At the agency, Høeg has allegedly floated the idea of preventing adolescent males from obtaining COVID-19 vaccines.

“She is an complete dogmatist who begins with her beliefs and works backwards to fit the evidence in a highly deceptive, untruthful fashion,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow dissenters, {like|